HTL.V - Hamilton Thorne Ltd


#142

HAMILTON THORNE TO ANNOUNCE Q2 2018 FINANCIAL RESULTS AND HOLD CONFERENCE CALL ON AUGUST 22, 2018

BEVERLY, Mass. and TORONTO, Aug. 09, 2018 (GLOBE NEWSWIRE) – Hamilton Thorne Ltd. (TSX-V:HTL), a leading worldwide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will release its financial results for the three and six months ended June 30, 2018 before market open on Wednesday, August 22, 2018. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedar.com.

The Company will follow with a conference call on the same day at 11:00 a.m. EDT to review highlights of the results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 3984088. A recording of the call will be available on Hamilton Thorne’s website shortly after the call.


#143

Hamilton Thorne Announces Record Revenue and EBITDA for the Quarter Ended June 30, 2018

Highlights

  • Sales increased 30% year over year to a record $7.3 million for the quarter; up 61% to $14.3 million for the six-month period; (constant currency growth of 28% for the quarter; 59% for the six-month period)

  • Gross profit increased 22% year over year to $4.1 million for the quarter; up 44% to $8.1 million for the six-month period

  • Net loss of $133 thousand for the quarter due to the change in fair value of debenture (see below); net income increased 74% year over year to $760 thousand for the six-month period

  • Adjusted EBITDA increased 7% year over year to a record $1.5 million for the quarter; up 39% to $3.1 million for the six-month period

  • 14% organic sales growth for the quarter; 16% for the six-month period

The Company will hold a conference call on Wednesday August 22, 2018 at 11:00 a.m. EDT to review highlights of results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 3984088. The Company’s updated investor presentation and a recording of the call will be available on Hamilton Thorne’s website shortly after the call.


#144

Hamilton Thorne Announces Completion of CDN $10,000,000 Bought Deal Private Placement

BEVERLY, Mass. and TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) – Hamilton Thorne Ltd. (TSX-V:HTL) (“Hamilton Thorne” or the “Company”), a leading worldwide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, announces the completion of its previously announced bought deal private placement. On closing, the Company issued an aggregate of 9,090,910 common shares of the Company (“Common Shares”) at a price of CDN$1.10 per Common Share (the “Offering Price”) for aggregate gross proceeds of CDN$10,000,001 (the “Offering”). The Offering was led by Bloom Burton Securities Inc. on behalf of a syndicate comprised of Beacon Securities Limited and Cormark Securities Inc. (collectively, the “Underwriters”).

The net proceeds of the Offering will be used for funding cash consideration of future acquisitions and general working capital purposes.

In connection with their services, the Underwriters received a total cash commission of approximately $600,000 and 545,454 non-transferable broker warrants (“Broker Warrants”). Each Broker Warrant is exercisable for a period of 12 months into one common share of Hamilton Thorne at a price of CDN$1.10 per common share.

All securities issued under the Offering will be subject to a four month hold period from the closing date under applicable Canadian securities laws. The Offering is subject to receipt of final acceptance from the TSX Venture Exchange.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.


#145

J’ai rencontré David Wolf (PDG) à Vancouver jeudi dernier. Voici quelques notes:

  • Suite au récent financement (bought deal), l’encaisse actuelle se situe aux alentours de 13 millions $ US.

  • Le financement n’a pas été réalisé en vue d’une acquisition immédiate, sinon l’acquisition aurait été annoncée au même moment. Cependant, l’objectif est de réaliser une ou plusieurs acquisitions éventuellement avec cet argent.

  • Lorsque j’ai demandé à David pourquoi il a levé l’argent maintenant s’il n’avait pas une acquisition à réaliser immédiatement, il a mentionné qu’un large investisseur institutionnel ainsi que plusieurs autres plus petits voulaient prendre position. Il est difficile de refuser de l’argent surtout lorsque le financement est proposé à un prix très près du haut de 52 semaines.

  • Depuis l’acquisition de Gynemed, la liste de cibles potentielles d’acquisition pour HTL s’est élargie pour inclure plus d’opportunités en Europe. Le fait que HTL est maintenant bien établi en Europe avec Gynemed fait en sorte qu’il est plus facile d’intégrer / gérer de plus petites acquisitions dans cette région.

  • L’Asie n’est pas dans les plans d’acquisitions pour l’instant. Les entreprises sont soit trop petites pour faire une réelle différence ou trop grosses au point que ça devient risqué financièrement et opérationnellement pour HTL de procéder.

  • Acquisition de ZANDAIR: les revenus étaient d’environ 50% de ventes d’équipements et 50% d’éléments consommables (à utilisation unique, ce qui procure des revenus récurrents). L’entreprise n’était pas bien gérée et sous-performais. David croît que les revenus ont le potentiel de doubler l’année prochaine, ce qui est assez significatif.

  • Concernant la croissance organique de 16% jusqu’à présent cette année, David est prudent et mentionne que cela dépasse assurément l’objectif interne qui est de 10%. Il ne peut pas pointer vers un élément exceptionnel qui aurait contribué à la forte croissance, mais croît qu’il pourrait y avoir un retour vers la moyenne de 10% éventuellement.

  • Pour ce qui est des marges brutes, le niveau actuel (56-57%) devrait être soutenable à court terme, quoique ‘‘lumpy’’ un peu (pourrait fluctuer autour de cette cible). À long terme, les marges brutes devraient s’améliorer grâce au modèle de ventes directes aux États-Unis.

D’un point de vue plus intangible, à chaque fois que je rencontre David je trouve qu’il est l’un des PDG de microcaps les plus solides que je connais. Je mettrais également Ryan Pape de XPEL dans la même catégorie.


#146

BEVERLY, Mass. and TORONTO, Nov. 13, 2018 (GLOBE NEWSWIRE) – Hamilton Thorne Ltd. (TSX-V: HTL), a leading worldwide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will release its financial results for the three and nine months ended September 30, 2018 before market open on Tuesday, November 20, 2018. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedar.com.

The Company will follow with a conference call on the same day at 11:00 a.m. EST to review highlights of the results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 2546617. A recording of the call will be available on Hamilton Thorne’s website one day after the call.